2-(N-tert-butoxycarbonyl-N'-pyridin-3-ylhydrazino)-3-(2'-chloro-4',5'-difluorobiphenyl-4-yloxymethyl)benzoic acid methyl ester | 1299467-23-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(N-tert-butoxycarbonyl-N'-pyridin-3-ylhydrazino)-3-(2'-chloro-4',5'-difluorobiphenyl-4-yloxymethyl)benzoic acid methyl ester
• 英文别名: 2-(N'-tert-butoxycarbonyl-N'-pyridin-3-yl-hydrazino)-3-(4',5'-difluoro-2'-chloro-biphenyl-4-yloxymethyl)-benzoic acid methyl ester；methyl 3-[[4-(2-chloro-4,5-difluorophenyl)phenoxy]methyl]-2-[2-[(2-methylpropan-2-yl)oxycarbonyl]-2-pyridin-3-ylhydrazinyl]benzoate
• CAS: 1299467-23-4
• 化学式: C₃₁H₂₈ClF₂N₃O₅
• 分子量: 596.03
• InChiKey: UFMSSGURIOXKFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  90
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-(N-tert-butoxycarbonyl-N'-pyridin-3-ylhydrazino)-3-(2'-chloro-4',5'-difluorobiphenyl-4-yloxymethyl)benzoic acid methyl ester 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.5h， 以72%的产率得到7-(4',5'-difluoro-2'-chlorobiphenyl-4-yloxymethyl)-2-pyridin-3-yl-1,2-dihydroindazol-3-one
  参考文献：
  名称：

  Design and synthesis of 2-N-substituted indazolone derivatives as non-carboxylic acid glycogen synthase activators

  摘要：

  Glycogen synthase (GS) catalyzes the transfer of glucose residues from UDP-glucose to a glycogen polymer chain, a critical step for glucose storage. Patients with type 2 diabetes normally exhibit low glycogen levels and decreased muscle glucose uptake is the major defect in whole body glucose disposal. Therefore, activating GS may provide a potential approach for the treatment of type 2 diabetes. In order to identify non-carboxylic acids GS activators, we designed and synthesized a series of 2-N-alkyl- and 2-N-aryl-indazolone derivatives and studied their activity in activating human GS. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.049
• 作为产物：
  描述：

  2-溴-3-(溴甲基)苯甲酸甲酯 在 palladium diacetate 、 potassium carbonate 、 caesium carbonate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 5.0h， 生成 2-(N-tert-butoxycarbonyl-N'-pyridin-3-ylhydrazino)-3-(2'-chloro-4',5'-difluorobiphenyl-4-yloxymethyl)benzoic acid methyl ester
  参考文献：
  名称：

  Design and synthesis of 2-N-substituted indazolone derivatives as non-carboxylic acid glycogen synthase activators

  摘要：

  Glycogen synthase (GS) catalyzes the transfer of glucose residues from UDP-glucose to a glycogen polymer chain, a critical step for glucose storage. Patients with type 2 diabetes normally exhibit low glycogen levels and decreased muscle glucose uptake is the major defect in whole body glucose disposal. Therefore, activating GS may provide a potential approach for the treatment of type 2 diabetes. In order to identify non-carboxylic acids GS activators, we designed and synthesized a series of 2-N-alkyl- and 2-N-aryl-indazolone derivatives and studied their activity in activating human GS. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.049

文献信息

• INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS
  申请人：Bolin David Robert

  公开号：US20110112147A1

  公开（公告）日：2011-05-12

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  本文提供了公式(I)的化合物，以及其药用盐，其中取代基如规范中所披露。这些化合物及含有它们的药物组合物对于治疗代谢性疾病和紊乱，例如II型糖尿病等，具有用处。
• [EN] INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS<br/>[FR] DÉRIVÉS INDAZOLONE EN TANT QU'ACTIVATEURS DE GLYCOGÈNE SYNTHASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011057993A1

  公开（公告）日：2011-05-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.